Momenta’s Glatopa Shown to Have a Weak Market Position Compared to Teva’s Copaxone According to Recent Study by Spherix Global Insights
Download Report Overview The research, based on input from 85 US based physicians, also reveals continuing pressure on platform injectables in favor of earlier use of oral agents such as Sanofi’s Aubagio, Novartis’ Gilenya and Biogen’s Tecfidera ZUG, Switzerland, May 18, 2016 /PRNewswire/ — A recent study conducted by Spherix Global Insights found that Teva’s Copaxone continues to […]
New Study Indicates High Therapy Switching Rates for Multiple Sclerosis Patients in the US & EU, Benefitting Biogen’s Tecfidera, Novartis’ Gilenya & Sanofi’s Aubagio
Download Report Overview The research, based on analysis of over 2,100 patient records and input from over 400 neurologists, also reveals high anticipation and market opportunity for Roche’s ocrelizumab. April 14, 2016 – Zug, Switzerland – A recent study conducted by Spherix Global Insights found that the use of oral DMTs significantly increase at the expense […]
Payers Expected to Push Use of Sandoz’s Glatopa; Effectively Tying Neurologists’ Hands
Over 65% of neurologists believe that payers will make generic Copaxone a step edit in multiple sclerosis therapy, according to Spherix Global Insights, GmbH September 28, 2015 – Zug, Switzerland –Feedback gathered from 99 neurologists in the most recent release of RealTime Dynamix: Multiple Sclerosis reveals that the uptake of generic Copaxone will most likely […]
